Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are an entrepreneurial pharmaceutical company focused on the discovery, development and commercialization of medicines that improve patients' lives. At Ironwood, we're focused on three goals: transforming knowledge into medicines that make a difference for patients, creating value that will earn the continued support of our fellow stockholders, and building a team that passionately pursues excellence. If we do these things well, we hope to earn the right to continue doing them and, one step at a time, build an enduring pharmaceutical company that helps patients lead better lives. We have one marketed product, linaclotide, which is available in the United States under the trademarked name LINZESS and was recently approved in the European Union under the trademarked name Constella. Linaclotide is also being developed in other parts of the world by certain of our partners. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.68 |
| Quarterly EPS Est: | -0.71 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
2.82 |
Data is provided by Zacks Investment Research
